Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.55 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.55 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29390847 | 0.96 | GABRA1 (0.58) | GABRA1GABRB2MGLLTP53MAPT | |
| SCHEMBL36294 | 0.96 | GABRA1 (0.58) | GABRA1GABRB2MGLLTP53MAPT | |
| SCHEMBL25425763 | 0.96 | GABRA1 (0.58) | GABRA1GABRB2MGLLTP53MAPT | |
| SCHEMBL30988351 | 0.93 | GABRA1 (0.55) | GABRA1GABRB2MGLLTP53MAPT | |
| Ammonia Solution, Strong SCHEMBL2638008 | 0.93 | GABRA1 (0.55) | GABRA1GABRB2MGLLTP53MAPT | |
| Benzene SCHEMBL11603070 | 0.93 | TP53 (0.56) | GABRA1GABRB2MGLLTP53MAPT | |
| SCHEMBL14807864 | 0.93 | GABRA1 (0.55) | GABRA1GABRB2MGLLTP53MAPT | |
| SCHEMBL25402639 | 0.93 | GABRA1 (0.55) | GABRA1GABRB2MGLLTP53MAPT | |
| Benzene SCHEMBL3122858 | 0.93 | TP53 (0.56) | GABRA1GABRB2MGLLTP53MAPT | |
| SCHEMBL28866250 | 0.93 | GABRA1 (0.55) | GABRA1GABRB2MGLLTP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020038049-A1 | SULPHONATION PROCESS AND NOVEL SULPHONATED COMPOUNDS | MANRO PERFOMANCE CHEMICALS LIMITED (GB) | 2002-03-28 | — | — | US | disclosed |
| EP-0998453-A1 | SULPHONATION PROCESS AND NOVEL SULPHONATED COMPOUNDS | Manro Performance Chemicals Limited (GB) | 2000-05-10 | — | — | EP | disclosed |
| WO-1999061415-A1 | SULPHONATION PROCESS AND NOVEL SULPHONATED COMPOUNDS | MANRO PERFORMANCE CHEMICALS LIMITED (GB) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020038049-A1 | SULPHONATION PROCESS AND NOVEL SULPHONATED COMPOUNDS | TST, STS, SULT2A1 | GABRA1 650/4885GABRB2 266/4885MGLL 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.